Abstract:Benign prostatic hyperplasia (BPH) as a common geriatric disease in urology, the incidence and prevalence are rapidly increasing with the aging society, prompting an urgent need for effective prevention and treatment of BPH. However, limited therapeutic efficacy and higher risk of complications result in the treatment of BPH remaining challenging. The unclear pathogenic mechanism also hampers further exploration of therapeutic approaches for BPH. In this study, we used multi-omics methods to integrate genomics, transcriptomics, immunomics, and metabolomics data and identify biomolecules associated with BPH. We performed transcriptomic imputation, summary data-based Mendelian randomization (SMR), joint/conditional analysis, colocalization analysis, and FOCUS to explore high-confidence genes associated with BPH in blood and prostate tissue. Subsequently, three-step SMR was used to identify the DNA methylation sites regulating high-confidence genes to improve the pathogenic pathways of BPH. We also used cis-instruments of druggable genes to conduct SMR analysis to find potential drug targets for BPH. Finally, we used MR analysis to explore the immune pathways and metabolomics related to BPH. Multiple analytical methods identified BTN3A2 (Blood: TWAS Z score = 5.02912, TWAS P = 4.93 × 10 –7 ; Prostate: TWAS Z score = 4.89, TWAS P = 1.01 × 10 –6 ) and C4A (Blood: TWAS Z score = 4.90754, TWAS P = 9.22 × 10 –7 ; Prostate: TWAS Z score = 5.084, TWAS P = 3.70 × 10 –7 ) as high-confidence genes for BPH and identified the cg14345882- BTN3A2 -BPH pathogenic pathway. We also used druggable gene data to identify 30 promising therapeutic target genes, including BTN3A2 and C4A . For MR analysis of immune pathways, we identified immune cell surface molecules as well as the inflammatory factor IL-17 (OR = 1.25, 95% CI = 1.09–1.43, P FDR = 0.12, Maximum likelihood) as risk factors for BPH. In addition, we found that disulfide levels of cysteinylglycine (OR = 1.11, 95% CI = 1.05–1.18, P = 5.18 × 10 –4 , Weighted median), oxidation levels of cysteinylglycine (OR = 1.09, 95% CI = 1.04–1.14, P = 3.87 × 10 –4 , Weighted median), and sebacate levels (OR = 1.05, 95% CI = 1.02–1.08, P = 3.0 × 10 –4 , Maximum likelihood) increase the risk of BPH. This multi-omics study explored biomolecules associated with BPH, improved the pathogenic pathways of BPH, and identified promising therapeutic targets. Our results provide evidence for future studies aimed at developing appropriate therapeutic interventions.

Comparative RNA-sequencing Analysis of the Prostate in a Mouse Model of Benign Prostatic Hyperplasia with Bladder Outlet Obstruction.

Animal models of benign prostatic hyperplasia

Single-cell analysis reveals alternations between the aged and young mice prostates

Identification Of Key Genes And Pathways In Benign Prostatic Hyperplasia

Mitogen-Activated Protein Kinase Pathway and Four Genes Involved in the Development of Benign Prostatic Hyperplasia: <i>In Vivo</i> and <i>Vitro</i> Validation

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Cross-species Comparison of Orthologous Gene Expression in Human Bladder Cancer and Carcinogen-Induced Rodent Models.

A genetic study to identify pathogenic mechanisms and drug targets for benign prostatic hyperplasia: a multi-omics Mendelian randomization study

Bulk mRNA-seq data from wild-type and prostate cancer-developing mice reveal a reprogramming of the estrogen and androgen responses after carcinogenesis

Exploration of diagnostic biomarkers, microenvironment characteristics, and ursolic acid's therapeutic effect for benign prostate hyperplasia

Integrative exploration of the mutual gene signatures and immune microenvironment between benign prostate hyperplasia and castration-resistant prostate cancer

PROSTATE CELL HETEROGENEITY AND CXCL17 UPREGULATION IN MOUSE STEROID HORMONE IMBALANCE

Establishing and Characterizing the Molecular Profiles, Cellular Features, and Clinical Utility of a Patient-Derived Xenograft Model Using Benign Prostatic Tissues

Expression Profiling of the Mouse Prostate after Castration and Hormone Replacement: Implication of H-cadherin in Prostate Tumorigenesis.

S100A4 modulates cell proliferation, apoptosis and fibrosis in the hyperplastic prostate

391 Upregulation of Phosphodiesterase Type 4 in the Hyperplastic Prostate

SLC25A37 is Casually Associated with the Increased Incidence of Benign Prostatic Hyperplasia

Alteration of the Expression and Functional Activities of Myosin II Isoforms in Enlarged Hyperplastic Prostates

Prostatic androgen receptor signaling shows an age-related and lobe-specific alteration in mice

Prostate-specific antigen, androgen, progesterone and oestrogen receptors in Benign prostatic hyperplasia: human tissues and animal model study

Deep RNA-Seq Analysis Reveals Unexpected Features of Human Prostate Basal Epithelial Cells